<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50260">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01890629</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL012</org_study_id>
    <nct_id>NCT01890629</nct_id>
  </id_info>
  <brief_title>Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on MAGE in Patients With Type 2 DM</brief_title>
  <official_title>A Multicenter, Randomized, Active-controlled, Parallel Group, Open-label, Exploratory Study to Evaluate the Efficacy on MAGE (Mean Amplitude of Glycemic Excursions) and Safety of Initial Combination Therapy of Gemigliptin 50mg q.d., Versus Sitagliptin 100mg q.d., or Glimepiride 2mg q.d. With Metformin 500-1,000mg q.d. in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare efficacy and safety of initial combination therapy of Gemigliptin versus
      Sitagliptin or Glimepiride with Metformin on MAGE (mean amplitude of glyclemic excursion) in
      Patients With Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Amplitude Glycemic Excursion</measure>
    <time_frame>Change of MAGE at Week 12 from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>Change of Glucagon at Week 12 from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active GLP-1</measure>
    <time_frame>Change of Active GLP-1 at Week 12 from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>Change of CRP at Week 12 from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrotyrosine</measure>
    <time_frame>Change of nitrotyrosine at Week 12 from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated albumin</measure>
    <time_frame>Change of glycated albumin at Week 4 from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine</measure>
    <time_frame>Change of fructosamine at Week 4 from baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Gemigliptin + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin + Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride + Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin</intervention_name>
    <arm_group_label>Gemigliptin + Metformin</arm_group_label>
    <arm_group_label>Sitagliptin + Metformin</arm_group_label>
    <arm_group_label>Glimepiride + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Type 2 Diabetes Mellitus

          -  adults aged ≥ 20 and aged  ≤ 70 years old

          -  Patients who had not taken anti diabetes drug for 8 weeks prior to screening visit
             with HbA1c ≥ 7.5%

          -  All patients give written informed consent

          -  Patients applicable to any one of following 3 categories

               1. Patients with surgically induced infertility

               2. Post-menopause woman ≥45 years of age with over 2 years from the last
                  menstruation

               3. Fertile pre-menopause woman or male patients who has consented for use of two or
                  more contraceptive methods at least  up to 14 days after final administration of
                  the investigational product to avoid getting pregnant

        Exclusion Criteria:

          -  Patients with Type 1 Diabetes, Patients with Diabetic Ketoacidosis or Diabetic Coma
             as well as Pre-coma

          -  Patients with Gestational Diabetes Mellitus or with Secondary Diabetes

          -  Patients with NYHA Class III, IV Congestive Heart Failure or with Treatment-requiring
             Arrhythmia

          -  Patients with Thyroid Dysfunction whose TSH is out of normal range, requiring
             medication therapy

          -  Patients with pituitary insufficiency or hypoadrenalism

          -  Patients whose BMI is less than 20 Kg/m2 or exceeds 40 Kg/m2

          -  Patients whose Total Bilirubin level is 1.5 times higher than the upper limit of
             normal range and ALT/AST are &gt; 2.5 times higher than the upper limit of normal range

          -  Patients currently taking strong CYP3A4 inducers

          -  Patients currently taking Warfarin, Dicoumar or Digoxin

          -  Patients currently taking any medication from within 4 weeks before Visit 1
             (screening) likely to have significant effects on glycemic control or who require to
             take such medication

          -  Patients who had taken anti-obesity drugs within 12 weeks in prior to Visit 1
             (screening)

          -  Subject who had been treated with Insulin or GLP-1 analogue within 6 months before
             Visit 1 (screening)

          -  Patients who had participated in other clinical study in the past 3 months before
             Visit 1 (screening)

          -  Any other patients whom the investigator considers as inadequate for this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SE Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangbuk Samsung Medical center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BW Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JH Jo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JH Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JH Jung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YoungHwan Jang</last_name>
    <phone>82-2-6924-3158</phone>
    <email>younghj@lgls.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BW Lee</last_name>
    </contact>
    <investigator>
      <last_name>BW Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 27, 2013</lastchanged_date>
  <firstreceived_date>May 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Sitagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
